CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CRON - CA22717L1013 - Common Stock
3.71 CAD
-0.02 (-0.54%)
We assign a fundamental rating of 4 out of 10 to CRON. CRON was compared to 35 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. CRON is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRON was profitable.
CRON had a positive operating cash flow in the past year.
In the past 5 years CRON reported 4 times negative net income.
CRON had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of CRON (3.06%) is better than 80.00% of its industry peers.
CRON has a Return On Equity of 3.33%. This is in the better half of the industry: CRON outperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROIC | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CRON's Profit Margin of 27.27% is amongst the best of the industry. CRON outperforms 94.29% of its industry peers.
CRON's Profit Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 43.35%, CRON is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRON has been increased compared to 1 year ago.
Compared to 5 years ago, CRON has more shares outstanding
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 7.90 indicates that CRON is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.90, CRON belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.9 |
ROIC/WACCN/A
WACC8.37%
2.3 Liquidity
A Current Ratio of 22.45 indicates that CRON has no problem at all paying its short term obligations.
CRON has a Current ratio of 22.45. This is amongst the best in the industry. CRON outperforms 100.00% of its industry peers.
CRON has a Quick Ratio of 21.28. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 21.28, CRON belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 |
3. Growth
3.1 Past
CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 283.33%, which is quite impressive.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
Looking at the last year, CRON shows a quite strong growth in Revenue. The Revenue has grown by 19.00% in the last year.
CRON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.71% yearly.
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
3.2 Future
CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 7.39% on average per year.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 24.73, which indicates a rather expensive current valuation of CRON.
71.43% of the companies in the same industry are more expensive than CRON, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CRON to the average of the S&P500 Index (27.25), we can say CRON is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 37.46, the valuation of CRON can be described as expensive.
62.86% of the companies in the same industry are more expensive than CRON, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, CRON is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.73 | ||
| Fwd PE | 37.46 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
5. Dividend
5.1 Amount
CRON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CRON (1/12/2026, 7:00:00 PM)
3.71
-0.02 (-0.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners15.01%
Inst Owner ChangeN/A
Ins Owners6.28%
Ins Owner ChangeN/A
Market Cap1.42B
Revenue(TTM)132.36M
Net Income(TTM)36.10M
Analysts82.86
Price Target5.1 (37.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.4%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-5%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)-0.21%
Revenue beat(8)3
Avg Revenue beat(8)-1.43%
Revenue beat(12)4
Avg Revenue beat(12)-1.97%
Revenue beat(16)6
Avg Revenue beat(16)-3.29%
PT rev (1m)0%
PT rev (3m)112.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-8.28%
Revenue NQ rev (3m)-8.28%
Revenue NY rev (1m)-1.71%
Revenue NY rev (3m)-1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.73 | ||
| Fwd PE | 37.46 | ||
| P/S | 7.74 | ||
| P/FCF | N/A | ||
| P/OCF | 47.08 | ||
| P/B | 0.95 | ||
| P/tB | 1.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.15
EY4.04%
EPS(NY)0.1
Fwd EY2.67%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY2.12%
SpS0.48
BVpS3.92
TBVpS3.65
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.64
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% | ||
| FCFM | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 209.86% | ||
| Cap/Sales | 20.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 | ||
| Altman-Z | 7.9 |
F-Score6
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
Revenue Next Year11.03%
Revenue Next 2Y20.49%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y70.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year119.92%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y93.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.89%
OCF growth 3YN/A
OCF growth 5YN/A
CRONOS GROUP INC / CRON.CA FAQ
What is the fundamental rating for CRON stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRON.CA.
What is the valuation status of CRONOS GROUP INC (CRON.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to CRONOS GROUP INC (CRON.CA). This can be considered as Overvalued.
What is the profitability of CRON stock?
CRONOS GROUP INC (CRON.CA) has a profitability rating of 3 / 10.
What is the valuation of CRONOS GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CRONOS GROUP INC (CRON.CA) is 24.73 and the Price/Book (PB) ratio is 0.95.